ILab
Seongnam, Kyonggi-do, South Korea
About ILab
ILAB is a research firm that specializes in the development of new immune target compounds that overcome biopharmaceutical limitations. The company is developing a small-molecule tumor necrosis factor that can be administered orally, allowing physicians to use low immunogenicity drugs to treat rheumatoid arthritis and other related diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Last round: Series Unknown (Jan 2019)
- Website: ilab.co.kr
- Phone: 02-6952-4088
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/ilab-2583771 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.